

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1439 Abstraction, Virginia 22313-1450 www.lapto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/847,048	05/01/2001	YongQi Mu	P-091-R	5200
27038	7590 09/29/2003			
THERAVANCE, INC.			EXAMINER	
901 GATEWAY BOULEVARD SOUTH SAN FRANCISCO, CA 94080			KAM, CHIH MIN	
			ART UNIT	PAPER NUMBER
			1653	
			DATE MAILED: 09/29/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/847,048	MU, YONGQI			
Office Action Summary	Examiner	Art Unit			
•	Chih-Min Kam	1653			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re  - If NO period for reply is specified above, the maximum statutory perio  - Failure to reply within the set or extended period for reply will, by statu.  - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).  Status	l. 1.136(a). In no event, however pply within the statutory mini d will apply and will expire S ute, cause the application to	ver, may a reply be timely filed mum of thirty (30) days will be considered timely. SIX (6) MONTHS from the mailing date of this communication. become ABANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on	·				
2a) This action is <b>FINAL</b> . 2b) 7	This action is non-fir	nal.			
3) Since this application is in condition for allow					
closed in accordance with the practice unde <b>Disposition of Claims</b>	er Ex parte Quayle,	1935 C.D. 11, 453 O.G. 213.			
4)⊠ Claim(s) <u>1-21</u> is/are pending in the application	on.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.	•				
8) Claim(s) <u>1-21</u> are subject to restriction and/or	r election requireme	ent.			
Application Papers					
9) The specification is objected to by the Examin					
10) The drawing(s) filed on is/are: a) acc		•			
Applicant may not request that any objection to t		•			
11) The proposed drawing correction filed on					
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120	.xammer.				
13) Acknowledgment is made of a claim for foreign	an priority under 25	II S C S 110(a) (d) ar (f)			
a) ☐ All b) ☐ Some * c) ☐ None of:	gn phonty under 33	0.3.0. § 119(a)-(a) of (i).			
	nte have been receiv	ved			
<ul><li>1. Certified copies of the priority documents have been received.</li><li>2. Certified copies of the priority documents have been received in Application No</li></ul>					
3. Copies of the certified copies of the pri					
application from the International B  * See the attached detailed Office action for a lis	ureau (PCT Rule 17	7.2(a)).			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
<ul> <li>a) ☐ The translation of the foreign language present</li> <li>15)☐ Acknowledgment is made of a claim for domes</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 1	Interview Summary (PTO-413) Paper No(s) Notice of Informal Patent Application (PTO-152) Other:			

Application/Control Number: 09/847,048

Art Unit: 1653

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U. S. C. 121:
  - I. Claims 1-17, drawn to a glycopeptide compound having at least one substitution of the formula -R<sup>a</sup>-Y-R<sup>b</sup>-(Z)<sub>x</sub>, and a pharmaceutical composition comprising the glycopeptide, classified in class 530, subclass 322.
  - II. Claims 18-21, drawn a method of treating a mammal having a bacterial disease comprising administering a glycopeptide having at least one substitution of the formula -R<sup>a</sup>-Y-R<sup>b</sup>-(Z)<sub>x</sub>, classified in class 530, subclass 322.

Should Invention I or II be elected, applicant is required to select one formula of a glycopeptide from formula (I) or (II) with each variable defined in the formula. Each glycopeptide compound with different amino acid sequence and different functional group, absent factual data to the contrary, is a distinct compound. This is not species election.

2. The inventions are distinct, each from the other because of the following reasons:

The product of Invention I and the method of Invention II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process of Invention II can be practiced with a known glycopeptide antibiotics, vancomycin (page 1, line 23-page 2, line 3 of the specification).

Application/Control Number: 09/847,048

Art Unit: 1653

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by the recognized divergent subject matter, and because Inventions I-II require different searches but are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

A telephone call was made to Jeffery Hagenah on September 24, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-0294 for regular communications and (703) 308-4227 for After Final communications.

Application/Control Number: 09/847,048

Art Unit: 1653

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D.

CMK

Patent Examiner

\*\*\*

September 24, 2003

CHRISTOPHER S. F. LOW IPERVISORY PATENT EXAMINER